Maimonides Biomedical Research Institute of Cordoba - IMIBIC
Organisation / Company Maimonides Biomedical Research Institute of Cordoba - IMIBIC Department GC06 Research Group “New Therapies in Cancer” Is the Hosting related to staff position within a Research Infrastructure? No
The consolidated research group GC06, “New Cancer Therapies,” affiliated with the Medical Oncology Department of the Reina Sofía University Hospital of Cordoba (HURS), as part of the Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), is launching a fellowship program for medical oncologists who have completed their residency. This initiative aims to provide a high-level training opportunity for young oncologists seeking to consolidate their professional development in an environment that combines excellence in patient care with clinical and translational research.
The program is part of a strategy to promote young talent in clinical research, in line with the priority areas of the Andalusian Plan for Research and Innovation in Health and with the post-residency training standards recommended by SEOM and ESMO.
The two-year program has a dual objective: to enhance the clinical competence of young oncologists and to facilitate their integration into the field of advanced clinical research. The fellow's time will be balanced, with approximately 30% dedicated to clinical practice and 70% to direct participation in clinical trials and research projects. This structure aims not only to develop technical skills but also to cultivate a critical and scientific perspective on medical practice.
The training program will be organized around a set of clinical, methodological, and research competencies defined according to European standards (ESMO/ANECA), with progressive objectives that allow for the evaluation of skills and knowledge acquisition throughout the program. The program will also guarantee the beneficiaries' continued employment within the Andalusian healthcare system, allowing them to maintain their active professional accreditation throughout their training period.
During their stay, beneficiaries will be fully integrated into the clinical team of the Medical Oncology Department at HURS, participating in outpatient consultations,



multidisciplinary sessions, and hospital activities, with a special emphasis on the management of patients enrolled in clinical trials. On the research side, they will actively participate in the development of ongoing clinical studies, collaborate in the design of new academic protocols, and receive specific training in Good Clinical Practice (GCP), research methodology, applied statistics, and scientific writing. The curriculum will also include training in clinical trial management and monitoring, scientific integrity, data protection, biobanks, and the ethical and regulatory aspects of biomedical research. The teaching methodology will combine in-person sessions, practical workshops, and online training, in line with recommendations for clinical-research specialization programs.
The program will feature a dual mentoring system. Each fellow will be assigned a clinical tutor—a member of the Medical Oncology Department—and a research tutor—from GC06—who will monitor their progress and provide personalized guidance for their training. Participants will also have access to IMIBIC's training programs and can attend national and international courses, seminars, and conferences to enhance their academic and scientific development. Each fellow will have an Individual Development Plan (IDP), developed in collaboration with their tutors, outlining the semester-long training objectives and competencies to be acquired. Tutors must demonstrate solid clinical and research experience (at least five years of clinical practice and three recent indexed publications), thus ensuring qualified supervision.
Over the course of two years, each recipient will be encouraged to develop a personal research project, framed within one of the Service's or Institute's active lines of research.



This project may serve as the basis for a future doctoral thesis or for the generation of new clinical knowledge. At the end of the grant period, participants must submit a final report detailing the results of their work, publications, presentations, and projects undertaken.
Each participant will be encouraged to complete the program with at least one conference presentation and one manuscript submitted or in preparation, thereby strengthening their competitiveness for programs such as Río Hortega, Juan Rodés, or SAS Actions.
The selected candidateswill receive specific training in writing competitive projects and applying for national and international research grants, including calls from ISCIII, ESMO and Horizon Europe.
Participation criteria and requirements.
The program is open to medical oncologists who have obtained their degree and who demonstrate an interest in and motivation for clinical research. Prior participation in clinical trials, completion of master's degrees or courses in research methodology, and involvement in scientific projects or publications will be highly valued.
A minimum level of scientific English equivalent to B2 or higher (CEFR) is recommended, enabling the critical reading of biomedical literature and participation in international forums. Prior experience with clinical databases, biological sample management, or clinical trial platforms will also be considered an asset.
Applicants must submit their application along with an updated curriculum vitae, a cover letter outlining their educational interests and reasons for participating in the program, and at least one letter of recommendation from a tutor or academic supervisor to the following email address:. The subject line of the email must include the reference B001/2026 ;
applications that do not include this reference in the subject line will not be evaluated.
The evaluation committee may request a personal interview to assess the candidate's suitability for the program profile.
The application period will be open permanently. Applications will be evaluated based on a transparent scoring system that will consider academic and scientific merits, clinical experience, the cover letter,
#J-18808-Ljbffr

📌 Translational Oncology Clinical Research Fellowship (Madrid)
🏢 Maimonides Biomedical Research Institute of Cordoba - IMIBIC
📍 Madrid